Get notified when PRGO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Goodwill Impairment (new) — Company recorded $330.8M total goodwill impairment in Q1 2026 across three reporting units following segment reorganization, with Women's Health and Skin Health units now having passing margins under 10%.
Perrigo posts $331M goodwill impairment, 7% revenue decline as restructuring accelerates
Filed May 6, 2026 · Period ending March 28, 2026 · Compared to 10-Q May 7, 2025 · ~2 min read
Key Changes
-
high
Company recorded $330.8M goodwill impairment across Women's Health, Infant Formula, and Oral Care units following segment reorganization, driving Q1 operating loss of $372M versus $47M profit prior year.
MD&A: Goodwill Impairment verify on EDGAR → -
high
Revenue declined 7.2% on 9.9% organic volume drop from lower consumption and reduced cough/cold incidence, accelerating from prior year's 3.5% decline driven primarily by divestitures.
MD&A: Revenue verify on EDGAR → -
high
Strategic review of infant formula business announced November 2025, reassessing previously planned $240M investment and considering full range of alternatives including potential divestiture.
MD&A: Infant Formula Strategic Review verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (THRM 10-Q) is open in full — no account needed.
Partner
Trade PRGO commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify